New therapeutic approach to slowdown the progression of Parkinson’s disease
NeuroSoV has won a grant for research and development in co-promotion from the Portuguese Government on April 2021. Such project involves 2 Portuguese Universities, University of Beira Interior (https://www.ubi.pt) and University of Aveiro (https://www.ua.pt), NeuroSoV and ih-Care (https://www.ihcare.pt/. Patients and society expect that technical and scientific advances can provide novel improved answers to address unmet medical needs. The absence of preventive therapies that interrupt the progression of PD requires the development of new therapeutic strategies. The oxidative stress process contributes for the progression of PD pathogenesis, being an ideal therapeutic target. Herein, we will test a chemical inhibitor that exhibited an exceptional neuroprotective effect in PD models. This project aims to prove the pharmacological efficacy and therapeutic application for PD of the reformulated inhibitor.
Ficha Técnica: https://www.dropbox.com/s/tly5ap5sg6lqkwv/Ficha%20Tecnica_PDSolve.tiff?dl=0
NeuroSoV at Websummit
NeuroSoV was live at the 2020 Websummit event, as invited speaker at the Masterclass Healthtech Lisboa: a new venture builder.
Won in the vertical University Pavilion STARTUP OLÉ 2020 DIGITAL EDITION PITCH COMPETITION #startupole organized by Startup OLÉ Accelerator.
New Experimental Model for PD research
NeuroSoV new scientific paper characterizing an Improved paraquat (PQ)-based rat model that recapitulates cardinal features of PD pathology. The new low dose of PQ exposure paradigm using osmotic minipumps, generated a rodent model of PD that reproduces increases of the nigrostriatal dopaminergic lesion, sustained neuroinflammation, oxidative stress and a-synuclein pathology overtime, complemented with the motor deficit. DOI: 10.1111/ejn.14683